Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Authors: Javier Cortés, David W. Cescon, Hope S. Rugo, Zbigniew Nowecki, Seock‐Ah Im et al.